

Please amend the claims as follows:

1-21. Canceled

22. (Previously presented) An isolated polypeptide consisting of X1-SHCIX2-X3 wherein X1 is 0-10 amino acids of the sequence ATTAGILATL (SEQ ID NO:41); X2 is E or Q; and X3 is 0-10 amino acids of the sequence LMVKREDSWQ (SEQ ID NO:42)

23. Canceled

24. (Previously presented) A pharmaceutical composition comprising the polypeptide of claim 22 and a pharmaceutically acceptable carrier.

25-33. Canceled

34. (New) The isolated polypeptide of claim 22 wherein X2 is E.

35. (New) The isolated polypeptide of claim 22 wherein X2 is Q.

36. (New) The isolated polypeptide of claim 22 wherein X1 is ILATL.

37. (New) The isolated polypeptide of claim 22 wherein X3 is LMKVR.

38. (New) A pharmaceutical composition comprising the polypeptide of claim 34 and a pharmaceutically acceptable carrier.

39. (New) A pharmaceutical composition comprising the polypeptide of claim 35 and a pharmaceutically acceptable carrier.

40. (New) A pharmaceutical composition comprising the polypeptide of claim 36 and a pharmaceutically acceptable carrier.

41. (New) A pharmaceutical composition comprising the polypeptide of claim 37 and a pharmaceutically acceptable carrier.

Support for the new claims

The new claims are supported, for example, in the claims as originally filed, and also on page 34 lines 1-4. Thus, the added claims do not constitute new matter.


Election

The Applicants hereby elect the invention of Group XIII, claims 22 and 24 for continued prosecution in this case. The election is made with traverse.

If the examiner believes it to be helpful, she is invited to contact the undersigned representative by telephone at (312) 913-2106.

Respectfully Submitted,

Date: 3/3/06

By: 
David S. Harper
Reg. No. 42,636

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001